EuroBiotech—More articles of note


> Shares in GeNeuro jumped more than 35% after the Swiss biotech posted post hoc analyses of its phase 2b multiple sclerosis trial. The rise partly offset the vertiginous drop the stock suffered earlier this year when GNbAC1 failed to beat placebo against the trial’s primary endpoint. Release 

> Poxel offloaded the rights to its diabetes drug in certain Asian countries to Sumitomo Dainippon Pharma. The deal lands Poxel a €36 million ($42 million) upfront payment, plus milestones and a partner to push Type 2 diabetes drug imeglimin to market in Japan and other Asian countries. Shares in Poxel rose more than 25% following the news. Statement

> Enterome brought its Crohn’s disease candidate through a phase 1 trial. The small molecule targets host-microbiome interaction in an attempt to curb the condition. Enterome is now gearing up for a phase 1b in patients with the disease. Release 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Apitope filed to list its stock in Brussels, Belgium. The IPO is intended to equip Apitope to take its multiple sclerosis candidate through a phase 2b trial. Apitope has phase 2a data linking the immunotolerizing agent to a drop in total and new neurological lesions. Merck KGaA ran that trial but dumped the program last year. Statement (PDF)

> ReNeuron detailed plans to shrink and truncate a planned U.S. trial of its stroke cell therapy. The smaller, shorter trial is scheduled to readout in the second half of 2019. ReNeuron thinks it will need to run a separate, pivotal trial to win approval. Release   

> Nanobiotix raised €27.2 million ($31.7 million) in a placement of shares. The fundraising sets Nanobiotix up to move lead candidate NBTXR3 into a checkpoint inhibitor combination trial in the U.S. Statement

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.